Multicenter, randomized, controlled trials evaluating mortality in intensive care: Doomed to fail?
暂无分享,去创建一个
[1] D. Altman. Statistics and ethics in medical research: III How large a sample? , 1980, British medical journal.
[2] The Veterans. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. , 1987, The New England journal of medicine.
[3] T. Clemmer,et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. , 1987, The New England journal of medicine.
[4] J. Schellekens,et al. Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial. , 1988, The Journal of infectious diseases.
[5] R. Bone,et al. An early test of survival in patients with the adult respiratory distress syndrome. The PaO2/FIo2 ratio and its differential response to conventional therapy. Prostaglandin E1 Study Group. , 1989, Chest.
[6] A. Ballabio,et al. Effects of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater. , 1991, Archives of surgery.
[7] C. Sprung,et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. , 1991 .
[8] A. Dubin,et al. Gastric intramucosal pH as a therapeutic index of tissue oxygenation in critically ill patients , 1992, The Lancet.
[9] S. Chevret,et al. A controlled trial in intensive care units of selective decontamination of the digestive tract with nonabsorbable antibiotics. The French Study Group on Selective Decontamination of the Digestive Tract. , 1992, The New England journal of medicine.
[10] C. Hinds,et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. , 1994, The New England journal of medicine.
[11] R. F. Johnston,et al. Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial , 1994 .
[12] K. Dickersin,et al. Systematic Reviews: Identifying relevant studies for systematic reviews , 1994 .
[13] S. Opal,et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. , 1994, JAMA.
[14] D G Altman,et al. Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology journals. , 1994, JAMA.
[15] R. J. Hayes,et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.
[16] Craig R. Smith,et al. Treatment of septic shock with human monoclonal antibody HA-1A: A randomized, double-blind, placebo-controlled trial , 1995 .
[17] M. Clarke,et al. Identifying relevant studies for systematic reviews , 1995, BMJ.
[18] N. MacIntyre,et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. , 1995, Critical care medicine.
[19] G. Koch,et al. Efficacy and Safety of Monoclonal Antibody to Human Tumor Necrosis Factor α in Patients With Sepsis Syndrome: A Randomized, Controlled, Double-blind, Multicenter Clinical Trial , 1995 .
[20] S. Nasraway,et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. , 1995, JAMA.
[21] I. Olkin,et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. , 1996, JAMA.
[22] S. Opal,et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. , 1996, The New England journal of medicine.
[23] A. Anzueto,et al. Aerosolized Surfactant in Adults with Sepsis-Induced Acute Respiratory Distress Syndrome , 1996 .
[24] D. Sackett,et al. Evidence based medicine: what it is and what it isn't , 1996, BMJ.
[25] J. Carlet,et al. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. , 1996, Critical care medicine.
[26] S. Opal,et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. , 1997, Critical care medicine.
[28] M. Schaller,et al. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group. , 1998, Critical care medicine.
[29] G. Meduri,et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. , 1998, JAMA.
[30] S. Nasraway,et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock , 1998, The Lancet.
[31] F Lemaire,et al. Tidal volume reduction for prevention of ventilator-induced lung injury in acute respiratory distress syndrome. The Multicenter Trail Group on Tidal Volume reduction in ARDS. , 1998, American journal of respiratory and critical care medicine.
[32] C. Carvalho,et al. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. , 1998, The New England journal of medicine.
[33] Arthur S Slutsky,et al. Evaluation of a ventilation strategy to prevent barotrauma in patients at high risk for acute respiratory distress syndrome. Pressure- and Volume-Limited Ventilation Strategy Group. , 1998, The New England journal of medicine.
[34] S. Kleinman,et al. A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care , 1999 .
[35] D. Gens,et al. Diaspirin Cross-Linked Hemoglobin (DCLHb) in the Treatment of Severe Traumatic Hemorrhagic Shock: A Randomized Controlled Efficacy Trial , 1999 .
[36] E J Topol,et al. Cause of death in clinical research: time for a reassessment? , 1999, Journal of the American College of Cardiology.
[37] J. Vincent. Which therapeutic interventions in critical care medicine have been shown to reduce mortality in prospective, randomized, clinical trials? A survey of candidates for the Belgian Board Examination in Intensive Care Medicine , 2000, Critical care medicine.
[38] OLAND,et al. TREATMENT OF SEPTIC SHOCK WITH THE TUMOR NECROSIS FACTOR RECEPTOR : Fc FUSION PROTEIN C , 2000 .
[39] F. Gordo,et al. Prospective randomized trial comparing pressure-controlled ventilation and volume-controlled ventilation in ARDS. For the Spanish Lung Failure Collaborative Group. , 2000, Chest.
[40] T. Similowski,et al. Invasive and Noninvasive Strategies for Management of Suspected Ventilator-Associated Pneumonia , 2000, Annals of Internal Medicine.
[41] F. Gordo,et al. Prospective randomized trial comparing pressure-controlled ventilation and volume-controlled ventilation in ARDS. For the Spanish Lung Failure Collaborative Group. , 2000, Chest.
[42] L. U. G. Attinoni,et al. A TRIAL OF GOAL-ORIENTED HEMODYNAMIC THERAPY IN CRITICALLY ILL PATIENTS , 2000 .
[43] Rian,et al. THE EFFECTS OF IBUPROFEN ON THE PHYSIOLOGY AND SURVIVAL OF PATIENTS WITH SEPSIS , 2000 .
[44] Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. The ARDS Network. , 2000, JAMA.
[45] J. A. Kruse,et al. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. , 2000, JAMA.
[46] D. Schoenfeld,et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. , 2000, The New England journal of medicine.
[47] J. Takala,et al. Effect of dopexamine on outcome after major abdominal surgery: A prospective, randomized, controlled multicenter study , 2000, Critical care medicine.
[48] Ook.,et al. EVALUATION OF A VENTILATION STRATEGY TO PREVENT BAROTRAUMA IN PATIENTS AT HIGH RISK FOR ACUTE RESPIRATORY DISTRESS SYNDROME , 2000 .
[49] G. Van den Berghe,et al. Increased mortality associated with growth hormone treatment in critically ill adults. , 2000, The New England journal of medicine.
[50] R. Kaplan,et al. A randomized clinical trial of continuous versus intermittent dialysis for acute renal failure. , 2001, Kidney international.
[51] J. Vincent,et al. A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin E1 (TLC C-53) in patients with acute respiratory distress syndrome , 2001, Intensive Care Medicine.
[52] S. Opal,et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. , 2001, JAMA.
[53] J. Vincent,et al. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study , 2001, Critical care medicine.
[54] Doctors' perceptions of the effects of interventions tested in prospective, randomised, controlled, clinical trials: results of a survey of ICU physicians , 2001, Intensive Care Medicine.
[55] D. Cook,et al. On the need for observational studies to design and interpret randomized trials in ICU patients: a case study in stress ulcer prophylaxis , 2001, Intensive Care Medicine.
[56] ntonio,et al. EFFECT OF PRONE POSITIONING ON THE SURVIVAL OF PATIENTS WITH ACUTE RESPIRATORY FAILURE , 2001 .
[57] Jorge A. López,et al. Early enteral nutrition in critically ill patients with a high-protein diet enriched with arginine, fiber, and antioxidants compared with a standard high-protein diet. The effect on nosocomial infections and outcome. , 2001, JPEN. Journal of parenteral and enteral nutrition.
[58] S. Opal,et al. High-Dose Antithrombin III in Severe Sepsis: A Randomized Controlled Trial , 2001 .
[59] J Ean,et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.
[60] P. Gay,et al. Noninvasive proportional assist ventilation for acute respiratory insufficiency. Comparison with pressure support ventilation. , 2001, American journal of respiratory and critical care medicine.
[61] T. Butler,et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients , 2001, Critical care medicine.
[62] J. Tijssen,et al. Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: A prospective, randomized trial , 2002, Critical care medicine.
[63] Peter Jüni,et al. Quality of reporting of randomized trials as a measure of methodologic quality. , 2002, JAMA.
[64] Arthur S Slutsky,et al. Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome , 2002, Critical care medicine.
[65] J. Karlawish,et al. The continuing unethical conduct of underpowered clinical trials. , 2002, JAMA.
[66] J. Vincent,et al. Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis* , 2003, Critical care medicine.
[67] A. Norrby-Teglund,et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[68] Steven B. Johnson,et al. Multicenter evaluation of a human monoclonal antibody to Entero-bacteriaceae common antigen in patients with Gram-negative sepsis , 2003, Critical care medicine.
[69] Jill P Pell,et al. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. , 2004, The International journal of prosthodontics.
[70] Michel Wolff,et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. , 2003, JAMA.
[71] R. Brant,et al. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. , 2003, The New England journal of medicine.
[72] L. Brochard,et al. Early use of the pulmonary artery catheter and outcomes in patients with shock and acute respiratory distress syndrome: a randomized controlled trial. , 2003, JAMA.
[73] Stephen F. Lowry,et al. Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure , 2003, Critical care medicine.
[74] C. Sprung,et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. , 2003, JAMA.
[75] Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock , 2003, Current infectious disease reports.
[76] Quoc V. Le,et al. Effects of systematic prone positioning in hypoxemic acute respiratory failure: a randomized controlled trial. , 2004, JAMA.
[77] Robert W. Taylor,et al. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. , 2004, JAMA.
[78] Robyn Norton,et al. A comparison of albumin and saline for fluid resuscitation in the Intensive Care unit , 2005 .
[79] G. Bernard,et al. Neutrophil elastase inhibition in acute lung injury: Results of the STRIVE study , 2004, Critical care medicine.
[80] Steven B. Johnson,et al. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels* , 2004, Critical care medicine.
[81] Margaret M Parker,et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock , 2004, Critical care medicine.
[82] J. Kievit,et al. Effects of transfusion with red cells filtered to remove leucocytes: randomised controlled trial in patients undergoing major surgery , 2004, BMJ : British Medical Journal.
[83] A. Anzueto,et al. Noninvasive positive-pressure ventilation for respiratory failure after extubation. , 2004, The New England journal of medicine.
[84] S. Opal,et al. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial* , 2004, Critical care medicine.
[85] J. Bakker,et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock* , 2004, Critical care medicine.
[86] R. Brand,et al. Double-Blind, Randomized Controlled Trial on the Effect of Leukocyte-Depleted Erythrocyte Transfusions in Cardiac Valve Surgery , 2004, Circulation.
[87] J. Vincent. Evidence-based medicine in the ICU: important advances and limitations. , 2004, Chest.
[88] Marek Ancukiewicz,et al. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. , 2009, The New England journal of medicine.
[89] J. Chiche,et al. High-volume hemofiltration after out-of-hospital cardiac arrest: a randomized study. , 2005, Journal of the American College of Cardiology.
[90] R. Rossaint,et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. , 2005, The New England journal of medicine.
[91] A. Dmitrienko,et al. LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis* , 2005, Critical care medicine.
[92] M. Singer,et al. Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care ( PAC-Man ) : a randomised controlled trial , 2022 .
[93] B. Druss. Evidence based medicine: does it make a difference? , 2005, BMJ : British Medical Journal.
[94] R. Kacmarek,et al. A high positive end-expiratory pressure, low tidal volume ventilatory strategy improves outcome in persistent acute respiratory distress syndrome: A randomized, controlled trial* , 2006, Critical care medicine.
[95] M. Meade,et al. Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis? , 2006, Critical care.
[96] Gordon R Bernard,et al. Comparison of two fluid-management strategies in acute lung injury. , 2006, The New England journal of medicine.
[97] W. Hiddemann,et al. IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: A randomized, controlled, multiple-center trial* , 2006, Critical care medicine.
[98] G. Bernard,et al. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. , 2006, The New England journal of medicine.
[99] R. Hyzy,et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. , 2006, The New England journal of medicine.
[100] R. Haynes,et al. Comparison of top-performing search strategies for detecting clinically sound treatment studies and systematic reviews in MEDLINE and EMBASE. , 2006, Journal of the Medical Library Association : JMLA.
[101] Didier Payen,et al. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study* , 2006, Critical care medicine.
[102] Arthur S Slutsky,et al. Partial liquid ventilation in adult patients with acute respiratory distress syndrome. , 2006, American Journal of Respiratory and Critical Care Medicine.
[103] Rafael Fernández,et al. A multicenter trial of prolonged prone ventilation in severe acute respiratory distress syndrome. , 2006, American journal of respiratory and critical care medicine.
[104] Lung. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. , 2009 .
[105] Lung. Efficacy and Safety of Corticosteroids for Persistent Acute Respiratory Distress Syndrome , 2009 .